Ignite Creation Date:
2025-12-25 @ 4:56 AM
Ignite Modification Date:
2026-01-20 @ 3:45 PM
Study NCT ID:
NCT01437618
Status:
COMPLETED
Last Update Posted:
2011-09-21
First Post:
2011-07-12
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer
Sponsor:
Azienda Ospedaliero, Universitaria Pisana
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
BRAF-0809-TRIBV
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None